Results 11 to 20 of about 68,932 (288)

Invitro fertilization outcome in triggering with GnRH agonist, Hcg or combination of GnRH agonist and Hcg [PDF]

Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2020
Introduction: Human chorionic gonadotropin for the final maturation of eggs in the In-vitro fertilization cycle was associated with the possibility of a negative effect on endometrial acceptance, fetal quality and ovarian hyper stimulation syndrome ...
Alamtaj Samsami, Sara Davoodi, Shaghayegh Moradi Alamdarloo, Tahere Poordast, Zahra Shiravani, Azade Morshedzadeh   +5 more
doaj   +1 more source

Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

Scientific Reports, 2021
Gonadotropin-releasing hormone agonist (GnRH-a) is generally added to the improve pregnancy outcomes of hormone replacement therapy cycles among patients with adenomyosis.
M. Li, L. Xu, H. Zhao, L. Yan, Y. Du
semanticscholar   +1 more source

Obstetric and neonatal outcomes after programmed frozen embryo transfer with or without GnRH agonist for polycystic ovary syndrome: secondary analysis results from a randomized controlled trialAJOG Global Reports at a Glance

AJOG Global Reports, 2023
BACKGROUND: Recent studies have reported higher risks of adverse maternal and neonatal outcomes, such as hypertensive disorders of pregnancy, after programmed frozen embryo transfer, especially in cycles with gonadotropin-releasing hormone agonist ...
Hui-ying Jie, MD, Ruifang Hu, BS, Limei Zhang, MD, Kexin Dong, MD, Chunyan Wu, MD, Qiong Wang, MD, Lu Luo, MD   +6 more
doaj   +1 more source

Luteal-phase support in assisted reproductive technology: An ongoing challenge

International Journal of Reproductive BioMedicine, 2021
It has been shown that in controlled ovarian hyper stimulation cycles, defective luteal phase is common. There are many protocols for improving pregnancy outcomes in women undergoing fresh and frozen in vitro fertilization cycles.
Saeideh Dashti, Maryam Eftekhar
doaj   +1 more source

Luteal Support and Risk of Ovarian Hyperstimulation in Assisted Reproduction (A Review)

Кубанский научный медицинский вестник, 2020
Background. Gonadotropin-releasing hormone agonist as an ovulation trigger effectively reduces the ovarian hyperstimulation risk in in vitro fertilisation protocols, at the same time requiring an effective luteal phase support in embryo transfer cycles ...
V. A. Krutova, A. A. Baklakova
doaj   +1 more source

Aвтоимун тироидит по долга употреба на агонист на гонадотропин- ослободувачки хормон како третман за предвремен централен пубертет – приказ на случај [PDF]

, 2020
There is a small number of studies that have reported abnormalities in endocrine function after a long-term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls. This treatment is considered as safe and effective by most authors.
Krstevska-Konstantinova, Marina, Kuzevska-Maneva, Konstandina, Murtezani, Avdi, Tankoska, Maja   +3 more
core   +2 more sources

Modified cytoskeletal and extracellular matrix composition in the canine testis after long-acting gonadotropin-releasing hormone agonist deslorelin treatment. [PDF]

Andrology
Abstract Background Long‐acting gonadotropin‐releasing hormone (GnRH) agonists are commonly used for fertility control in male dogs. Their effect on testicular histomorphology has not been clarified. Objectives To elucidate the mechanisms underlying androgen withdrawal in response to long‐acting GnRH agonist deslorelin 4.7 mg treatment on testicular ...
Gram A, Abay M, Gram DY, Liman N, Müller L, Balogh O.   +5 more
europepmc   +2 more sources

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The risk of cardiac dysfunction for patients with prostate cancer undergoing androgen deprivation therapy (ADT) in the real‐world setting remains unclear.
Dong‐Yi Chen, Cheng‐Hung Lee, Ming‐Lung Tsai, Ming‐Jer Hsieh, Cheng‐Keng Chuang, See‐Tong Pang, Shao‐Wei Chen, Chi‐Nan Tseng, Shang‐Hung Chang, Pao‐Hsien Chu, I‐Chang Hsieh, Victor Chien‐Chia Wu, Wen‐Kuan Huang   +12 more
doaj   +1 more source

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist [PDF]

Endocrinology and Metabolism, 2013
Gonadotropin-releasing hormone (GnRH) agonist has been used in the treatment of a wide variety of sex-hormone-related diseases, as the administration of GnRH agonist can alter the secretion of gonadotropin and sex hormones.
Eun Jin Han, Ha Do Song, Ji Hoon Yang, So Young Park, Sung Hoon Kim, Hyun Koo Yoon, Chang Hoon Yim   +6 more
doaj   +1 more source

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy [PDF]

Journal of the Endocrine Society, 2021
Abstract Background: Gonadotropin-releasing hormone agonists (GnRHa), used in the treatment of prostate cancer (PC) and for reproductive purposes in women, have been implicated as the cause of pituitary apoplexy (PA), a potentially life-threatening condition.
Yu, Xiaoling, Guarda, Francisco J, Shiraliyeva, Naila, Haines, Melanie S, Saylor, Philip J, Nachtigall, Lisa B   +5 more
openaire   +1 more source